TNFRSF17 genomic profiling guides retreatment with alternative BCMA-directed immunotherapies in multiple myeloma
Benjamin Podvin(Inserm), Salomon Manier(Université de Lille), Gauthier Decool(Inserm), Nicolas Gower(Centre Hospitalier Universitaire de Lille), Hélène Demarquette(Ikerbasque), Claude Preudhomme(Centre Hospitalier Universitaire de Lille), Inès Arib(Centre Hospitalier Universitaire de Lille), Rémi Tilmont(Centre Hospitalier Universitaire de Lille), Victoria Cacheux(Centre Hospitalier Universitaire de Clermont-Ferrand), Daniela Robu(Centre Hospitalier de Lens), Morgane Nudel(Centre Hospitalier Universitaire de Lille), Nicolas Duployez(Inserm), Doriane Cavalieri(University of Clermont Auvergne), Emmanuelle Bourgeois(Hôpital Claude Huriez), Thierry Facon(Université de Lille), Holly Lee(University of Calgary), Paola Neri(University of Calgary), Aurélie Caillault(Centre Hospitalier Universitaire de Lille), Nizar Bahlis(University of Calgary), Sabine Tricot(Centre Hospitalier de Valenciennes)
Cited by 0
Related Papers
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2018|1k
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
|The Lancet|2012|1k